HALEON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 325.1 GBX | +0.12% |
|
+0.65% | +1.07% |
| 21/05 | Bernstein becomes more optimistic for consumer goods - Henkel upgraded | DP |
| 17/05 | UK's FTSE 100 Closes Lower Amid Inflation Focus | MT |
| Sales 2024 * | 11.45B 14.59B 1,217B | Sales 2025 * | 11.93B 15.2B 1,268B | Capitalization | 29.69B 37.83B 3,155B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.46B 1.86B 155B | Net income 2025 * | 1.69B 2.15B 179B | EV / Sales 2024 * | 3.28 x |
| Net Debt 2024 * | 7.82B 9.96B 831B | Net Debt 2025 * | 7.08B 9.02B 752B | EV / Sales 2025 * | 3.08 x |
| P/E ratio 2024 * |
20.3
x | P/E ratio 2025 * |
17.6
x | Employees | 25,408 |
| Yield 2024 * |
1.9% | Yield 2025 * |
2.19% | Free-Float | 81.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Haleon plc
More press releases
| 1 day | +0.12% | ||
| 1 week | +0.65% | ||
| 1 month | -4.24% | ||
| 3 months | -1.92% | ||
| 6 months | -1.50% | ||
| Current year | +1.07% |
1 week
320.40
326.60
1 month
320.40371.20
Current year
308.37371.20
1 year
306.80371.20
3 years
241.17371.20
5 years
241.17371.20
10 years
241.17371.20
| Managers | Title | Age | Since |
|---|---|---|---|
Brian McNamara
CEO | Chief Executive Officer | 57 | 22/21/22 |
Tobias Hestler
DFI | Director of Finance/CFO | 52 | 01/21/01 |
Franck Riot
CTO | Chief Tech/Sci/R&D Officer | - | 16/21/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bryan Supran
BRD | Director/Board Member | - | 18/22/18 |
Dame Cox
BRD | Director/Board Member | 64 | 18/22/18 |
Tracy Clarke
BRD | Director/Board Member | 57 | 18/22/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 142 M€ | +12.59% | - | |
| 0.99% | 11 M€ | +0.83% | - | |
| 0.94% | 5 M€ | +15.85% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 325.1 | +0.12% | 51,827,680 |
| 30/24/30 | 324.7 | +0.84% | 37,319,470 |
| 29/24/29 | 322 | -0.59% | 43,432,510 |
| 28/24/28 | 323.9 | +0.28% | 30,423,870 |
| 24/24/24 | 323 | -1.79% | 14,185,250 |
Delayed Quote London S.E., May 31, 2024 at 09:05 pm IST
More quotes
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.251
GBP
Average target price
3.62
GBP
Spread / Average Target
+11.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.07% | 37.78B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- HLN Stock
